岩舒注射液治疗中晚期肿瘤患者75例的临床观察

Clinical Observation on Treatment of 75 Mid-late Stage Cancer Patients with Yanshu Injection

目的探讨岩舒注射液(复方苦参注射液)对综合治疗中晚期肿瘤的作用。方法将150例恶性肿瘤患者随机分为综合治疗组(简称综合组)和对照组,每组75例,均按照NCCN2005临床肿瘤治疗指南进行系统治疗,综合组在对照组基础上加用岩舒注射液20ml/d治疗。结果对照组血浆T淋巴细胞亚群CD4、CD4/CD8比值较综合组明显降低(P<0.05),对照组、综合组的有效率(responserate,RR)分别是32.00%(24/75)、38.67%(29/75),两组比较,差异无显著性(P>0.05),临床受益率(clinicalbenefitrate,CBR)分别是58.67%(44/75)、85.33%(64/75),两组比较,差异有显著性(P<0.05),综合组生活质量明显优于对照组(P<0.05),综合组治疗中化疗药物常见的不良反应发生率较对照组明显降低(P<0.05)。结论岩舒注射液能够调节肿瘤患者T淋巴细胞亚群的功能,提高肿瘤治疗的总体CBR,明显降低放化疗的不良反应,提高生活质量。

Objective To study the effect of Yanshu Injection （YI） used in comprehensive treatment on mid-late stage cancer. Methods One hundred and fifty patients with malignant cancer were equally randomized into the comprehensive treatment group （group A） and the control group （group B）, both groups were treated systematically according to the NCCN 2005 cancer practice guideline, but 20 ml of YI was given additionally to group A every day. Results After treatment, the level of plasma CD4 and CD4/CD8 ratio were significantly lower in group B than those in group A （P〈0.05）; the response rate （RR） was 32.00% （24/75） and 38.67 % （29/75） in group B and A respectively, showing insignificant difference （P 〉0.05）, and the clinical benefit rate （CBR）was 58.67% （44/75） in group A, lower than that in group B [85.33% （64/75）, P〈 0.05]; the quality of life （QOL） in group A was superior to that in group B （P〈0.05）; and the incidence of main adverse reaction to chemotherapeutic agents was significantly lower in group A as compared to that in group B （P〈0.05）. Conclusion YI could regulate the function of T-lymphocyte subsets, raise the CBR and QOL and reduce adverse reaction of chemotherapy in patients with mid-late stage cancer.